The Johnson & Johnson COVID-19 vaccine “is no longer available in the U.S.,” the U.S. Centers for Disease Control and Prevention (CDC) stated in a recent update.
That’s due to the vaccine expiring on May 7. Health care workers were advised to dispose of any remaining doses in accordance with regulations.
But uptake slowed after U.S. authorities paused recommending the vaccine because of concerns about a reported link to a combination of blood clotting and low platelet levels, a condition called thrombosis with thrombocytopenia syndrome (TTS) that can cause death. About 15 percent of the post-vaccination TTS cases have been fatal.
Regulators limited the availability of the vaccine in 2022 because experts determined it caused TTS.
Since March, recipients have also been warned that they face an increased risk of myocarditis, or heart inflammation, and a related condition called pericarditis. All four COVID-19 vaccines authorized in the United States present an increased risk of myocarditis, primarily for young males.
As of May 11, 19 million Johnson & Johnson shots have been administered, compared to more than 403 million Pfizer shots, more than 252 million Moderna shots, and about 89,000 Novavax shots, according to data reported to the CDC.
The Johnson & Johnson COVID-19 vaccine “is no longer available in the U.S.,” the U.S. Centers for Disease Control and Prevention (CDC) stated in a recent update.
That’s due to the vaccine expiring on May 7. Health care workers were advised to dispose of any remaining doses in accordance with regulations.
But uptake slowed after U.S. authorities paused recommending the vaccine because of concerns about a reported link to a combination of blood clotting and low platelet levels, a condition called thrombosis with thrombocytopenia syndrome (TTS) that can cause death. About 15 percent of the post-vaccination TTS cases have been fatal.
Regulators limited the availability of the vaccine in 2022 because experts determined it caused TTS.
Since March, recipients have also been warned that they face an increased risk of myocarditis, or heart inflammation, and a related condition called pericarditis. All four COVID-19 vaccines authorized in the United States present an increased risk of myocarditis, primarily for young males.
As of May 11, 19 million Johnson & Johnson shots have been administered, compared to more than 403 million Pfizer shots, more than 252 million Moderna shots, and about 89,000 Novavax shots, according to data reported to the CDC.